166 related articles for article (PubMed ID: 34302042)
21. Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis.
Domvri K; Petanidis S; Zarogoulidis P; Anestakis D; Tsavlis D; Bai C; Huang H; Freitag L; Hohenforst-Schmidt W; Porpodis K; Katopodi T
Clin Immunol; 2021 Jan; 222():108620. PubMed ID: 33176208
[TBL] [Abstract][Full Text] [Related]
22. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML.
Wang L; Jia B; Claxton DF; Ehmann WC; Rybka WB; Mineishi S; Naik S; Khawaja MR; Sivik J; Han J; Hohl RJ; Zheng H
Oncoimmunology; 2018; 7(9):e1469594. PubMed ID: 30228937
[TBL] [Abstract][Full Text] [Related]
23. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
Thakkar D; Paliwal S; Dharmadhikari B; Guan S; Liu L; Kar S; Tulsian NK; Gruber JJ; DiMascio L; Paszkiewicz KH; Ingram PJ; D Boyd-Kirkup J
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131861
[TBL] [Abstract][Full Text] [Related]
24. VISTA: Coming of age as a multi-lineage immune checkpoint.
ElTanbouly MA; Schaafsma E; Noelle RJ; Lines JL
Clin Exp Immunol; 2020 May; 200(2):120-130. PubMed ID: 31930484
[TBL] [Abstract][Full Text] [Related]
25. Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant.
Wang B; Ou Z; Zhong W; Huang L; Liao W; Sheng Y; Guo Z; Chen J; Yang W; Chen K; Huang X; Yang T; Lin T; Huang J
Cancer Immunol Res; 2023 Dec; 11(12):1656-1670. PubMed ID: 37847894
[TBL] [Abstract][Full Text] [Related]
26. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
Zhao T; Liu S; Hanna NH; Jalal S; Ding X; Wan J; Yan C; Du H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914206
[TBL] [Abstract][Full Text] [Related]
27. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
Liu J; Yuan Y; Chen W; Putra J; Suriawinata AA; Schenk AD; Miller HE; Guleria I; Barth RJ; Huang YH; Wang L
Proc Natl Acad Sci U S A; 2015 May; 112(21):6682-7. PubMed ID: 25964334
[TBL] [Abstract][Full Text] [Related]
28. Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer.
Wang J; Yang L; Yu L; Wang YY; Chen R; Qian J; Hong ZP; Su XS
Oncotarget; 2017 Mar; 8(10):17050-17058. PubMed ID: 28178645
[TBL] [Abstract][Full Text] [Related]
29. Loss of MLL Induces Epigenetic Dysregulation of Rasgrf1 to Attenuate Kras-Driven Lung Tumorigenesis.
Zhu LY; Yuan JB; Zhang L; He CX; Lin X; Xu B; Jin GH
Cancer Res; 2022 Nov; 82(22):4153-4163. PubMed ID: 36098964
[TBL] [Abstract][Full Text] [Related]
30. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
31. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
32. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment.
Zhang H; Huang H; Wu S; He X; Chen J; Zheng X; Chen L; Wang Z
Med Oncol; 2023 Aug; 40(10):285. PubMed ID: 37653265
[TBL] [Abstract][Full Text] [Related]
33. VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms.
Zhang K; Zakeri A; Alban T; Dong J; Ta HM; Zalavadia AH; Branicky A; Zhao H; Juric I; Husich H; Parthasarathy PB; Rupani A; Drazba JA; Chakraborty AA; Ching-Cheng Huang S; Chan T; Avril S; Wang LL
Cell Rep; 2024 Jan; 43(1):113661. PubMed ID: 38175754
[TBL] [Abstract][Full Text] [Related]
34. VISTA Blockade Aggravates Bone Loss in Experimental Murine Apical Periodontitis.
Yang F; Zhang Y; Chen Z; Zhang L
Front Immunol; 2021; 12():738586. PubMed ID: 34691045
[TBL] [Abstract][Full Text] [Related]
35. VISTA is an immune checkpoint molecule for human T cells.
Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
[TBL] [Abstract][Full Text] [Related]
36. Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis.
Fu X; Liu S; Cao D; Li C; Ji H; Wang G
Br J Cancer; 2024 Mar; 130(5):716-727. PubMed ID: 38195889
[TBL] [Abstract][Full Text] [Related]
37. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
Liang M; Sun Z; Chen X; Wang L; Wang H; Qin L; Zhao W; Geng B
J Exp Clin Cancer Res; 2023 Oct; 42(1):275. PubMed ID: 37865804
[TBL] [Abstract][Full Text] [Related]
38. High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response.
Tao T; Bo L; Li T; Shi L; Zhang H; Ye B; Xu Y; Ma Q; Deng X; Zhang G
Mediators Inflamm; 2021; 2021():6650329. PubMed ID: 34366711
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of Radiation Therapy through Blockade of the Immune Checkpoint, V-domain Ig Suppressor of T Cell Activation (VISTA), in Melanoma and Adenocarcinoma Murine Models.
Duval KEA; Tavakkoli AD; Kheirollah A; Soderholm HE; Demidenko E; Lines JL; Croteau W; Zhang SC; Wagner RJ; Aulwes E; Noelle RJ; Hoopes PJ
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762046
[TBL] [Abstract][Full Text] [Related]
40. M351-0056 is a novel low MW compound modulating the actions of the immune-checkpoint protein VISTA.
Hu X; Qie C; Jiang J; Xie X; Chen W; Liu W; Liu J
Br J Pharmacol; 2021 Mar; 178(6):1445-1458. PubMed ID: 33450048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
